newsfilter
← Latest News
Business Wire·

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential